Exploration of Targeted Anti-tumor Therapy

Study	Comparators	Study population	Primary outcome	Important results
T-DXd	DESTINY-Breast03 (n = 524)	T-DXd versus T-DM1	HER2-positive, unresectable and/or MBC, previously treated with trastuzumab and taxane	PFS (BICR)	HR 0.2840 (PFS not reached and 6.8 months, P = 7.8 × 10⁻²²)
Trastuzumab duocarmazine	TULIP (n = 437)	Trastuzumab duocarmazine versus treatment of physician’s choice	HER2-positive, locally advanced or MBC, ≥ 2 previous MBC regimens or previous treatment with T-DM1	PFS (BICR)	HR 0.64 (PFS 7.0 and 4.9 months, P = 0.002)
SG	ASCENT (n = 468)	SG versus single-agent chemotherapy of physician’s choice	TNBC relapsed or refractory to ≥ 2 previous standard chemotherapy for advanced or MBC, taxane must be included in the previous therapies	PFS (BICR)	HR 0.41 (5.6 and 1.7 months, P < 0.001)

Study

Comparators

Study population

Primary outcome

Important results

T-DXd

DESTINY-Breast03 (n = 524)

T-DXd versus T-DM1

HER2-positive, unresectable and/or MBC, previously treated with trastuzumab and taxane

PFS (BICR)

HR 0.2840 (PFS not reached and 6.8 months, P = 7.8 × 10⁻²²)

Trastuzumab duocarmazine

TULIP (n = 437)

Trastuzumab duocarmazine versus treatment of physician’s choice

HER2-positive, locally advanced or MBC, ≥ 2 previous MBC regimens or previous treatment with T-DM1

PFS (BICR)

HR 0.64 (PFS 7.0 and 4.9 months, P = 0.002)

ASCENT (n = 468)

SG versus single-agent chemotherapy of physician’s choice

TNBC relapsed or refractory to ≥ 2 previous standard chemotherapy for advanced or MBC, taxane must be included in the previous therapies

PFS (BICR)

HR 0.41 (5.6 and 1.7 months, P < 0.001)